Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 7, 2021; 27(29): 4818-4830
Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4818
Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4818
Table 1 Classification of direct-acting antiviral agents[29]
| Class | Drug name | HCV genotype |
| NS3/4A inhibitor | Boceprevir1 | Genotypes 1a and 1b |
| Telaprevir1 | ||
| Simeprevir | ||
| Asunaprevir | ||
| Paritaprevir | ||
| Grazoprevir | ||
| Glecaprevir | ||
| Voxilaprevir | ||
| NS5A inhibitor | Daclatasvir | All HCV genotypes |
| Ledipasvir | ||
| Ombitasvir | ||
| Elbasvir | ||
| Velpatasvir | ||
| Pibrentasvir | ||
| NS5B polymerase inhibitor: Nucleoside analogs | Sofosbuvir | All HCV genotypes |
| NS5B polymerase inhibitor: Non-nucleoside analogs | Dasabuvir | Genotypes 1a and 1b |
- Citation: Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021; 27(29): 4818-4830
- URL: https://www.wjgnet.com/1007-9327/full/v27/i29/4818.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i29.4818
